{"DataElement":{"publicId":"7615773","version":"1","preferredName":"Liver Toxicity Preventive Intervention Administered Therapeutic Procedure Type","preferredDefinition":"A description of the liver toxicity preventive intervention that was administered.","longName":"5036460v1.0:2789942v2.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5036460","version":"1","preferredName":"Liver Toxicity Preventive Intervention Administered","preferredDefinition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate._The finding of bodily harm due to the poisonous effects of something._In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet)._The act of having given something (e.g., a medication or test).","longName":"5036458v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5036458","version":"1","preferredName":"Liver Toxicity Preventive Intervention","preferredDefinition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.:The finding of bodily harm due to the poisonous effects of something.:In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).","longName":"C12392:C27990:C15843","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver","conceptCode":"C12392","definition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7F51-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-20","modifiedBy":"ONEDATA","dateModified":"2015-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7F5F-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-20","modifiedBy":"NYCHM","dateModified":"2017-02-01","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2789942","version":"2.1","preferredName":"Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Type; a subdivision of a particular kind of thing.","longName":"2789942v2.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Substrate deprivation / inhibitor","valueDescription":"Substrate Deprivation Therapy","ValueMeaning":{"publicId":"3005852","version":"1","preferredName":"Substrate Deprivation Therapy","longName":"3005852","preferredDefinition":"A therapeutic procedure based on the inhibition or reduction of the biosynthesis of compounds that cannot break down in the cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Substrate Deprivation Therapy","conceptCode":"C85876","definition":"A therapeutic procedure based on the inhibition or reduction of the biosynthesis of compounds that cannot break down in the cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EC6BD7C-DCC0-0DAC-E040-BB89AD435D56","latestVersionIndicator":"Yes","beginDate":"2010-02-04","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8A6-F93D-E050-BB89AD437D4E","beginDate":"2010-07-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Gene transfer / gene therapy","valueDescription":"Gene Therapy","ValueMeaning":{"publicId":"3082843","version":"1","preferredName":"Gene Therapy","longName":"3082843","preferredDefinition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.  The genetic material as 'naked' DNA can be delivered into the cells alone or can be delivered into cells by different types of vectors such as viruses which may contain DNA or RNA.  Gene therapy techniques attempt to replace a faulty/missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.  Gene therapies are designed to deliver genetic material into somatic cells and not germ cells, so that only cells of patients and not those of their offspring contain and express the genetic material delivered. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Therapy","conceptCode":"C15238","definition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85F4380C-67AF-77C6-E040-BB89AD4310D6","latestVersionIndicator":"Yes","beginDate":"2010-05-06","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-05-06","modifiedBy":"ONEDATA","dateModified":"2010-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8B0-F93D-E050-BB89AD437D4E","beginDate":"2010-07-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Enzyme replacement","valueDescription":"Protein Replacement Therapy","ValueMeaning":{"publicId":"2980740","version":"1","preferredName":"Protein Replacement Therapy","longName":"2980740","preferredDefinition":"Administration of a protein to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protein Replacement Therapy","conceptCode":"C16221","definition":"Administration of a protein to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the protein.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C844109-C20C-1B92-E040-BB89AD430E9F","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8BA-F93D-E050-BB89AD437D4E","beginDate":"2010-07-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Systemic therapy","valueDescription":"Systemic Therapy","ValueMeaning":{"publicId":"3102869","version":"1","preferredName":"Systemic Therapy","longName":"3102869","preferredDefinition":"(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8777A923-22E4-03B3-E040-BB89AD432D09","latestVersionIndicator":"Yes","beginDate":"2010-05-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-25","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt name for Alliance","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8C4-F93D-E050-BB89AD437D4E","beginDate":"2014-03-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8CE-F93D-E050-BB89AD437D4E","beginDate":"2013-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Pharmaceutical","valueDescription":"Pharmacologic Substance","ValueMeaning":{"publicId":"3913791","version":"1","preferredName":"Pharmacologic Substance","longName":"3913791","preferredDefinition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D5C0C6-EEFD-DBFF-E040-BB89AD432659","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8D8-F93D-E050-BB89AD437D4E","beginDate":"2013-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"None","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8E2-F93D-E050-BB89AD437D4E","beginDate":"2013-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Etanercept","valueDescription":"Etanercept","ValueMeaning":{"publicId":"5126589","version":"1","preferredName":"Etanercept","longName":"5126589","preferredDefinition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C25600F-CB7A-BDDC-E050-BB89AD434CE4","latestVersionIndicator":"Yes","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8EC-F93D-E050-BB89AD437D4E","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":"Infliximab","ValueMeaning":{"publicId":"3235990","version":"1","preferredName":"Infliximab","longName":"3235990","preferredDefinition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis.  Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-820D-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F8F6-F93D-E050-BB89AD437D4E","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Cyclosporine","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"3253643","version":"1","preferredName":"Cyclosporine","longName":"3253643","preferredDefinition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7A3A-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F900-F93D-E050-BB89AD437D4E","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F90A-F93D-E050-BB89AD437D4E","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Corticosteroids (systemic)","valueDescription":"Systemic Corticosteroid Therapy","ValueMeaning":{"publicId":"5127372","version":"1","preferredName":"Systemic Corticosteroid Therapy","longName":"5127372","preferredDefinition":"Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Corticosteroid Therapy","conceptCode":"C122080","definition":"Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F92E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F947-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Anti CD 25","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"5127373","version":"1","preferredName":"Daclizumab","longName":"5127373","preferredDefinition":"A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F951-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F969-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"ALG, ALS, ATG, ATS","valueDescription":"Anti-Thymocyte Globulin Antilymphocyte Serum","ValueMeaning":{"publicId":"3125119","version":"1","preferredName":"Anti-Thymocyte Globulin Antilymphocyte Serum","longName":"3125119","preferredDefinition":"A purified gamma immunoglobulin (IgG) with immunosuppressive activity.  Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes.  Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.: Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antilymphocyte Serum","conceptCode":"C62577","definition":"Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C9B96DB-0DE3-17DA-E040-BB89AD43253B","latestVersionIndicator":"Yes","beginDate":"2010-07-30","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F973-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"In vivo immunotoxin","valueDescription":"in vivo Immunotoxin","ValueMeaning":{"publicId":"5127391","version":"1","preferredName":"in vivo Immunotoxin","longName":"5127391","preferredDefinition":"Located or occurring in the body.: Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens) that targets affected cells allowing incorporation of the toxin into the cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotoxin","conceptCode":"C575","definition":"Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens) that targets affected cells allowing incorporation of the toxin into the cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F97E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F996-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"FK 506","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F9AA-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Extra-corporeal photopheresis (ECP)","valueDescription":"Extracorporeal Photopheresis","ValueMeaning":{"publicId":"5127392","version":"1","preferredName":"Extracorporeal Photopheresis","longName":"5127392","preferredDefinition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9B4-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F9CC-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Methotrexate (MTX)","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"5127393","version":"1","preferredName":"Methotrexate","longName":"5127393","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9D7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-F9EF-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"5127394","version":"1","preferredName":"Cyclophosphamide","longName":"5127394","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9F9-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FA11-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FA33-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"5127411","version":"1","preferredName":"Sirolimus","longName":"5127411","preferredDefinition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA4E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FA66-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Mycophenolate mofetil (MMF)","valueDescription":"Mycophenolate Mofetil","ValueMeaning":{"publicId":"3253642","version":"1","preferredName":"Mycophenolate Mofetil","longName":"3253642","preferredDefinition":"The mopholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-79F9-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FA7A-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"In vivo monoclonal antibody","valueDescription":"in vivo Monoclonal Antibody","ValueMeaning":{"publicId":"5127412","version":"1","preferredName":"in vivo Monoclonal Antibody","longName":"5127412","preferredDefinition":"Located or occurring in the body.: An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA84-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FA9C-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FABF-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Blinded randomized trial","valueDescription":"Blinded Randomized Clinical Trial","ValueMeaning":{"publicId":"5127414","version":"1","preferredName":"Blinded Randomized Clinical Trial","longName":"5127414","preferredDefinition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.: A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group. Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively. At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded","conceptCode":"C49068","definition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAC9-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FAE1-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"JAK 2 inhibitors","valueDescription":"JAK2 Inhibitor","ValueMeaning":{"publicId":"5127415","version":"1","preferredName":"JAK2 Inhibitor","longName":"5127415","preferredDefinition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAEC-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB05-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB0F-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"PUVA","valueDescription":"PUVA Photochemotherapy","ValueMeaning":{"publicId":"3865371","version":"1","preferredName":"PUVA Photochemotherapy","longName":"3865371","preferredDefinition":"Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PUVA Photochemotherapy","conceptCode":"C29973","definition":"Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4EDA99A-5CCA-ED23-E040-BB89AD4335E5","latestVersionIndicator":"Yes","beginDate":"2013-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB19-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Hydroxychloroquine","valueDescription":"Hydroxychloroquine","ValueMeaning":{"publicId":"3379074","version":"1","preferredName":"Hydroxychloroquine","longName":"3379074","preferredDefinition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxychloroquine","conceptCode":"C557","definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF6A-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB24-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Interleukin inhibitors","valueDescription":"Interleukin Inhibitor","ValueMeaning":{"publicId":"5127431","version":"1","preferredName":"Interleukin Inhibitor","longName":"5127431","preferredDefinition":"Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin Inhibitor","conceptCode":"C124064","definition":"Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB2E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB47-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":"Azathioprine","ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB51-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Aldesleukin","valueDescription":"Aldesleukin","ValueMeaning":{"publicId":"5127432","version":"1","preferredName":"Aldesleukin","longName":"5127432","preferredDefinition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldesleukin","conceptCode":"C1498","definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB5B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB73-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Tyrosine kinase inhibitors (TKI)","valueDescription":"Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"5127433","version":"1","preferredName":"Tyrosine Kinase Inhibitor","longName":"5127433","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB7E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FB96-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"5127434","version":"1","preferredName":"Rituximab","longName":"5127434","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBA0-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FBB8-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"UV therapy","valueDescription":"Ultraviolet Radiation","ValueMeaning":{"publicId":"2620311","version":"1","preferredName":"Ultraviolet Radiation","longName":"2620311","preferredDefinition":"The invisible ultraviolet spectrum makes up one specific portion of sunlight. This unique portion accounts for three percent of all solar radiation reaching the earth. UV radiation causes many health problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ultraviolet Radiation","conceptCode":"C17231","definition":"The invisible ultraviolet spectrum makes up one specific portion of sunlight. This unique portion accounts for three percent of all solar radiation reaching the earth. UV radiation causes many health problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CC11F71-6538-172B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-28","endDate":null,"createdBy":"CURTIST","dateCreated":"2007-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FBCC-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Defibrotide","valueDescription":"Defibrotide","ValueMeaning":{"publicId":"5127452","version":"1","preferredName":"Defibrotide","longName":"5127452","preferredDefinition":"A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Defibrotide Sodium","conceptCode":"C1064","definition":"A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBF7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FC10-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Ursodiol","valueDescription":"Ursodiol","ValueMeaning":{"publicId":"3380290","version":"1","preferredName":"Ursodiol","longName":"3380290","preferredDefinition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ursodiol","conceptCode":"C1818","definition":"A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A4DB-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FC25-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Tissue plasminogen activator (TPA)","valueDescription":"Tissue-Type Plasminogen Activator","ValueMeaning":{"publicId":"5127453","version":"1","preferredName":"Tissue-Type Plasminogen Activator","longName":"5127453","preferredDefinition":"Tissue-type plasminogen activator (562 aa, ~63 kDa) is encoded by the human PLAT gene. This protein plays a role in the cleavage of plasminogen between Arg-580 and Val-581 to form the fibrinolytic enzyme plasmin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tissue-Type Plasminogen Activator","conceptCode":"C16995","definition":"Tissue-type plasminogen activator (562 aa, ~63 kDa) is encoded by the human PLAT gene. This protein plays a role in the cleavage of plasminogen between Arg-580 and Val-581 to form the fibrinolytic enzyme plasmin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FC2F-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C5DDD88-FC48-F93D-E050-BB89AD437D4E","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Other therapy","valueDescription":"Other Therapeutic Procedure","ValueMeaning":{"publicId":"2746714","version":"1","preferredName":"Other Therapeutic Procedure","longName":"2746714","preferredDefinition":"Not otherwise specified.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C800309-2D53-62D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"2C5DDD88-F888-F93D-E050-BB89AD437D4E","beginDate":"2008-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Radiation","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2717922","version":"1","preferredName":"Radiation Therapy","longName":"2717922","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42BFA254-C33F-032A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"2C5DDD88-F892-F93D-E050-BB89AD437D4E","beginDate":"2008-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"2570169","version":"1","preferredName":"Chemotherapy","longName":"2570169","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DF26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"2C5DDD88-F89C-F93D-E050-BB89AD437D4E","beginDate":"2008-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"ONEDATA","dateModified":"2016-02-22","deletedIndicator":"No"},{"value":"N-acetylcysteine","valueDescription":"Acetylcysteine","ValueMeaning":{"publicId":"3128727","version":"1","preferredName":"Acetylcysteine","longName":"3128727","preferredDefinition":"A synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, a precursor of the antioxidant enzyme glutathione.  Acetylcysteine regenerates liver stores of glutathione. This agent also reduces disulfide bonds in mucoproteins, resulting in liquification of mucus.  Some evidence suggests that acetylcysteine may exert an anti-apoptotic effect due to its antioxidant activity, possibly preventing cancer cell development or growth.  In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetylcysteine","conceptCode":"C200","definition":"A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BEDD-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB3B8B1-1CC7-61BD-E050-BB89AD435482","beginDate":"2016-02-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Montelukast","valueDescription":"Montelukast","ValueMeaning":{"publicId":"5588941","version":"1","preferredName":"Montelukast","longName":"5588941","preferredDefinition":"The active ingredient in a drug used to treat symptoms of asthma, such as trouble breathing, tight chest, wheezing, coughing, and runny nose. Montelukast blocks the action of a substance that causes airways in the lungs to narrow and causes other symptoms of asthma. It is a type of leukotriene receptor antagonist and a type of antiasthmatic agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Montelukast","conceptCode":"C66189","definition":"A selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Upon administration, montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including migration of eosinophils and neutrophils, adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability, and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-9371-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B08557-938A-6CD6-E053-F662850A558E","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"Macrolide antibiotic","valueDescription":"Macrolide Antibiotic","ValueMeaning":{"publicId":"5588943","version":"1","preferredName":"Macrolide Antibiotic","longName":"5588943","preferredDefinition":"An anti-microbial compound comprised of a macrocyclic lactone with a ring of twelve or more members linked to one or more monosaccharides, with bacteriostatic and potential antifungal activities. Macrolide antibiotics generally inhibit protein synthesis by binding to the 50S subunit of the bacterial ribosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Macrolide Antibiotic","conceptCode":"C261","definition":"An anti-microbial compound comprised of a macrocyclic lactone with a ring of twelve or more members linked to one or more monosaccharides, with bacteriostatic and potential antifungal activities. Macrolide antibiotics generally inhibit protein synthesis by binding to the 50S subunit of the bacterial ribosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-9397-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B08557-93B0-6CD6-E053-F662850A558E","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"Ibrutinib","valueDescription":"Ibrutinib","ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B08557-93D3-6CD6-E053-F662850A558E","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"Treosulfan","valueDescription":"Treosulfan","ValueMeaning":{"publicId":"3922372","version":"1","preferredName":"Treosulfan","longName":"3922372","preferredDefinition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treosulfan","conceptCode":"C1257","definition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8F0C244-B505-23D8-E040-BB89AD430966","latestVersionIndicator":"Yes","beginDate":"2013-10-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-17","modifiedBy":"COOPERM","dateModified":"2020-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF6C824-CEEE-55DC-E053-F662850A6599","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Teniposide","valueDescription":"Teniposide","ValueMeaning":{"publicId":"2739552","version":"1","preferredName":"Teniposide","longName":"2739552","preferredDefinition":"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teniposide","conceptCode":"C857","definition":"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-026F-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF6C824-CEF8-55DC-E053-F662850A6599","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Paclitaxel","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF6C824-CF02-55DC-E053-F662850A6599","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Nitrosourea","valueDescription":"Nitrosourea Compound","ValueMeaning":{"publicId":"2829938","version":"1","preferredName":"Nitrosourea Compound","longName":"2829938","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"618DC679-B127-32DD-E040-BB89AD43461A","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF6C824-CF16-55DC-E053-F662850A6599","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Monoclonal antibody","valueDescription":"Monoclonal Antibody","ValueMeaning":{"publicId":"4232285","version":"1","preferredName":"Monoclonal Antibody","longName":"4232285","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4E6DCBF-18CA-667F-E040-BB89AD431523","latestVersionIndicator":"Yes","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF6C824-CF2A-55DC-E053-F662850A6599","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Other systemic therapy","valueDescription":"Other Systemic Therapy","ValueMeaning":{"publicId":"5805894","version":"1","preferredName":"Other Systemic Therapy","longName":"5805894","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-442D-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-4446-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Thioguanine","valueDescription":"Thioguanine","ValueMeaning":{"publicId":"2744957","version":"1","preferredName":"Thioguanine","longName":"2744957","preferredDefinition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thioguanine","conceptCode":"C876","definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80FC-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-4450-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-445A-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Midostaurin","valueDescription":"Midostaurin","ValueMeaning":{"publicId":"5805895","version":"1","preferredName":"Midostaurin","longName":"5805895","preferredDefinition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midostaurin","conceptCode":"C1872","definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4464-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"COOPERM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-447D-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Intrathecal therapy","valueDescription":"Intrathecal Route of Administration Therapeutic Procedure","ValueMeaning":{"publicId":"5805896","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure","longName":"5805896","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4487-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-44A0-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Decitabine","valueDescription":"Decitabine","ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-44AA-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"All-trans retinoic acid","valueDescription":"Tretinoin","ValueMeaning":{"publicId":"5342173","version":"1","preferredName":"Tretinoin","longName":"5342173","preferredDefinition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-3A61-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA05B60-44BE-1133-E053-F662850AB1AF","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Gemtuzumab","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505AEB16-4C41-6174-E053-F662850A7507","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Clofarabine","valueDescription":"Clofarabine","ValueMeaning":{"publicId":"3378889","version":"1","preferredName":"Clofarabine","longName":"3378889","preferredDefinition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofarabine","conceptCode":"C26638","definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-408F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505AEB16-4C4B-6174-E053-F662850A7507","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Arsenic","valueDescription":"Arsenic","ValueMeaning":{"publicId":"3971521","version":"1","preferredName":"Arsenic","longName":"3971521","preferredDefinition":"An element with atomic symbol As, atomic number 33, and atomic weight 74.92.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic","conceptCode":"C28131","definition":"A naturally occurring allotropic pnictogen and metalloid trace element with atomic symbol As, atomic number 33, and atomic weight 74.92 that is found in water, air, food, and soil, and has a role as a micronutrient. Arsenic, which is highly toxic with acute or chronic exposure to moderate or high levels through an unknown mechanism of action, is used in many industrial processes, as well as in pharmaceuticals, feed additives, and pesticides. It is characterized as a white, yellow, gray metallic, or black solid that is odorless. Exposure occurs by inhalation, ingestion, or contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC8E22AA-49ED-1FF6-E040-BB89AD4305B7","latestVersionIndicator":"Yes","beginDate":"2013-12-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2013-12-02","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505AEB16-4C57-6174-E053-F662850A7507","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Cladribine","valueDescription":"Cladribine","ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C6A-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"5544728","version":"1","preferredName":"Cisplatin","longName":"5544728","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCC725E-178D-054A-E053-F662850A831B","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"ZHANGW","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C74-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C7E-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C88-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Bleomycin","valueDescription":"Bleomycin","ValueMeaning":{"publicId":"2739540","version":"1","preferredName":"Bleomycin","longName":"2739540","preferredDefinition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBF7-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C92-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Anthracycline","valueDescription":"Anthracycline Antibiotic","ValueMeaning":{"publicId":"2750845","version":"1","preferredName":"Anthracycline Antibiotic","longName":"2750845","preferredDefinition":"A member of a family of anticancer drugs that are also antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9A553A-6F0D-6A30-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8C9C-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Mitoxantrone","valueDescription":"Mitoxantrone","ValueMeaning":{"publicId":"3518877","version":"1","preferredName":"Mitoxantrone","longName":"3518877","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4110B19-590C-CB86-E040-BB89AD431138","latestVersionIndicator":"Yes","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CA7-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Melphalan","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CB1-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Ifosfamide","valueDescription":"Ifosfamide","ValueMeaning":{"publicId":"2739548","version":"1","preferredName":"Ifosfamide","longName":"2739548","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01A4-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CBB-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":"Fludarabine","ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CC5-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CCF-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine","ValueMeaning":{"publicId":"3270479","version":"1","preferredName":"Cytarabine","longName":"3270479","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67D4-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EF419EA-8CD9-1ADA-E053-F662850AEDE7","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ONEDATA","dateModified":"2017-05-07","deletedIndicator":"No"},{"value":"Obinutuzumab","valueDescription":"Obinutuzumab","ValueMeaning":{"publicId":"5096860","version":"1","preferredName":"Obinutuzumab","longName":"5096860","preferredDefinition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obinutuzumab","conceptCode":"C70741","definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-4750-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B535-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":"Ponatinib","ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B53F-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"5805905","version":"1","preferredName":"Nilotinib","longName":"5805905","preferredDefinition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA044AC-B549-3351-E053-F662850A8B45","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B561-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Inotuzumab","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B575-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":"Imatinib","ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B57F-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B589-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA044AC-B593-3351-E053-F662850A8B45","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"Azacytidine","valueDescription":"Azacitidine","ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EC978F3-4E60-5473-E053-F662850A012C","beginDate":"2017-05-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-05","modifiedBy":"ONEDATA","dateModified":"2017-05-05","deletedIndicator":"No"},{"value":"Cytarabine (Ara - C) > 10 g/m2/cycle","valueDescription":"Greater Than 10 Gram per Square Meter Per Cycle Cytarabine","ValueMeaning":{"publicId":"5837559","version":"1","preferredName":"Greater Than 10 Gram per Square Meter Per Cycle Cytarabine","longName":"5837559","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.: For each, generally denoting a ratio.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Gram per Square Meter","conceptCode":"C67282","definition":"A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505C08A7-8662-43B7-E053-F662850AA78A","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505EAF91-5F2C-630A-E053-F662850A414C","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"5810420","version":"1","preferredName":"Thiotepa","longName":"Thiopeta","preferredDefinition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","context":"NHLBI","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F02410F-4E09-4DC7-E053-F662850A8F88","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F026C83-1D2F-516C-E053-F662850ACFB3","beginDate":"2017-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-08","modifiedBy":"ONEDATA","dateModified":"2017-05-08","deletedIndicator":"No"},{"value":"Siltuximab","valueDescription":"Siltuximab","ValueMeaning":{"publicId":"5621734","version":"1","preferredName":"Siltuximab","longName":"5621734","preferredDefinition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siltuximab","conceptCode":"C61084","definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BCF0-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F976041-2A50-4757-E053-F662850A9671","beginDate":"2017-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-16","modifiedBy":"ONEDATA","dateModified":"2017-05-16","deletedIndicator":"No"},{"value":"Cytarabine (Ara - C) <= 10 g/m2/cycle","valueDescription":"Less Than or Equal To 10 Gram per Square Meter Per Cycle Cytarabine","ValueMeaning":{"publicId":"5837560","version":"1","preferredName":"Less Than or Equal To 10 Gram per Square Meter Per Cycle Cytarabine","longName":"5837560","preferredDefinition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.: For each, generally denoting a ratio.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Less Than or Equal To","conceptCode":"C61586","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Gram per Square Meter","conceptCode":"C67282","definition":"A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505C08A7-868C-43B7-E053-F662850AA78A","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505C08A7-86A5-43B7-E053-F662850AA78A","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505C08A7-86AF-43B7-E053-F662850AA78A","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Idarubicin","valueDescription":"Idarubicin","ValueMeaning":{"publicId":"2744955","version":"1","preferredName":"Idarubicin","longName":"2744955","preferredDefinition":"A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin","conceptCode":"C562","definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80C8-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"505C08A7-86B9-43B7-E053-F662850AA78A","beginDate":"2017-05-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-25","modifiedBy":"ONEDATA","dateModified":"2017-05-25","deletedIndicator":"No"},{"value":"Other drug","valueDescription":"Other Pharmacologic Substance","ValueMeaning":{"publicId":"2775670","version":"1","preferredName":"Other Pharmacologic Substance","longName":"2775670","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0144-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F1D1854-A535-120B-E053-F662850AB09C","beginDate":"2017-05-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-09","modifiedBy":"ONEDATA","dateModified":"2017-05-09","deletedIndicator":"No"},{"value":"High dose methotrexate","valueDescription":"High Dose Chemotherapy Methotrexate","ValueMeaning":{"publicId":"5982054","version":"1","preferredName":"High Dose Chemotherapy Methotrexate","longName":"5982054","preferredDefinition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Dose Chemotherapy","conceptCode":"C15807","definition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A1ABB0-E46E-2339-E053-F662850A0746","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A1ABB0-E489-2339-E053-F662850A0746","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Bexarotene","valueDescription":"Bexarotene","ValueMeaning":{"publicId":"2567420","version":"1","preferredName":"Bexarotene","longName":"2567420","preferredDefinition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bexarotene","conceptCode":"C1635","definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D469-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"COOPERM","dateModified":"2017-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FDD8-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Ibritumomab tiuxetan","valueDescription":"Ibritumomab Tiuxetan","ValueMeaning":{"publicId":"2741549","version":"1","preferredName":"Ibritumomab Tiuxetan","longName":"2741549","preferredDefinition":"ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan.  This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90.  The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes one infusion of Rituximab preceding In-111 ZEVALIN. Step 2 follows Step 1 by seven to nine days and consists of a second infusion of Rituximab followed by Y-90 ZEVALIN.  ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibritumomab Tiuxetan","conceptCode":"C29981","definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-461A-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FDEC-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Everolimus","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE00-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Doxorubicin liposomal","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"2576633","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"2576633","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F866-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE14-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE1E-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Dacarbazine","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE28-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Carmustine","valueDescription":"Carmustine","ValueMeaning":{"publicId":"3378823","version":"1","preferredName":"Carmustine","longName":"3378823","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-158F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE32-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Brentuximab vedotin","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE46-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Bendamustine","valueDescription":"Bendamustine","ValueMeaning":{"publicId":"4862971","version":"1","preferredName":"Bendamustine","longName":"4862971","preferredDefinition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine","conceptCode":"C73261","definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1842453B-10A4-C393-E050-BB89AD436354","latestVersionIndicator":"Yes","beginDate":"2015-06-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-06-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE50-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE5B-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Ofatumumab","valueDescription":"Ofatumumab","ValueMeaning":{"publicId":"3243442","version":"1","preferredName":"Ofatumumab","longName":"3243442","preferredDefinition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofatumumab","conceptCode":"C66952","definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3256-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE65-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE6F-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Mogamulizumab","valueDescription":"Mogamulizumab","ValueMeaning":{"publicId":"5944042","version":"1","preferredName":"Mogamulizumab","longName":"5944042","preferredDefinition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mogamulizumab","conceptCode":"C62510","definition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FE7C-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE95-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FE9F-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"PEG-asparaginase","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FEB3-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"L-asparaginase","valueDescription":"Asparaginase","ValueMeaning":{"publicId":"3377440","version":"1","preferredName":"Asparaginase","longName":"3377440","preferredDefinition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase","conceptCode":"C286","definition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0D6-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FEC7-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Ixazomib","valueDescription":"Ixazomib","ValueMeaning":{"publicId":"5944043","version":"1","preferredName":"Ixazomib","longName":"5944043","preferredDefinition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixazomib","conceptCode":"C97940","definition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FED1-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FEEA-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FEF4-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Idelalisib","valueDescription":"Idelalisib","ValueMeaning":{"publicId":"5096863","version":"1","preferredName":"Idelalisib","longName":"5096863","preferredDefinition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idelalisib","conceptCode":"C78825","definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-479D-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E60930-FEFE-69F8-E053-F662850ABC19","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58875940-E23E-3DA7-E053-F662850ACC31","beginDate":"2017-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-06","modifiedBy":"ONEDATA","dateModified":"2017-09-06","deletedIndicator":"No"},{"value":"Vorinostat","valueDescription":"Vorinostat","ValueMeaning":{"publicId":"3380298","version":"1","preferredName":"Vorinostat","longName":"3380298","preferredDefinition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorinostat","conceptCode":"C1796","definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5B1-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8D63-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Vinorelbine","valueDescription":"Vinorelbine","ValueMeaning":{"publicId":"2576638","version":"1","preferredName":"Vinorelbine","longName":"2576638","preferredDefinition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8D6D-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Vincristine","valueDescription":"Vincristine","ValueMeaning":{"publicId":"3380295","version":"1","preferredName":"Vincristine","longName":"3380295","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A54A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8D77-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Vinblastine","valueDescription":"Vinblastine","ValueMeaning":{"publicId":"3380287","version":"1","preferredName":"Vinblastine","longName":"3380287","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A492-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8D81-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":"Venetoclax","ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DA4-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Tositumomab","valueDescription":"Tositumomab","ValueMeaning":{"publicId":"2741550","version":"1","preferredName":"Tositumomab","longName":"2741550","preferredDefinition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tositumomab","conceptCode":"C2543","definition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-4641-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DAE-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Temsirolimus","valueDescription":"Temsirolimus","ValueMeaning":{"publicId":"3380203","version":"1","preferredName":"Temsirolimus","longName":"3380203","preferredDefinition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temsirolimus","conceptCode":"C1844","definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D73C-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DB8-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DC2-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Romidepsin","valueDescription":"Romidepsin","ValueMeaning":{"publicId":"5342172","version":"1","preferredName":"Romidepsin","longName":"5342172","preferredDefinition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romidepsin","conceptCode":"C1544","definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-39D0-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DCC-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":"Procarbazine","ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DD6-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Pralatrexate","valueDescription":"10-Propargyl-10-Deazaaminopterin","ValueMeaning":{"publicId":"3379489","version":"1","preferredName":"10-Propargyl-10-Deazaaminopterin","longName":"3379489","preferredDefinition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pralatrexate","conceptCode":"C2250","definition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2623-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E65346-8DE0-6C22-E053-F662850A5722","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"High dose cytarabine","valueDescription":"High Dose Chemotherapy Cytarabine","ValueMeaning":{"publicId":"5981834","version":"1","preferredName":"High Dose Chemotherapy Cytarabine","longName":"5981834","preferredDefinition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Dose Chemotherapy","conceptCode":"C15807","definition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"599E430A-E16E-4562-E053-F662850A689F","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"599E430A-E187-4562-E053-F662850A689F","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Acalabrutinib","valueDescription":"Acalabrutinib","ValueMeaning":{"publicId":"6028593","version":"1","preferredName":"Acalabrutinib","longName":"6028593","preferredDefinition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acalabrutinib","conceptCode":"C113442","definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1C8E98-260C-503F-E053-F662850A8F36","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1C8E98-2625-503F-E053-F662850A8F36","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Copanlisib","valueDescription":"Copanlisib","ValueMeaning":{"publicId":"5982159","version":"1","preferredName":"Copanlisib","longName":"5982159","preferredDefinition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copanlisib","conceptCode":"C96796","definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A3C36F-85B0-32C0-E053-F662850ABBC1","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59A3C36F-85C9-32C0-E053-F662850ABBC1","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"ONEDATA","dateModified":"2017-09-20","deletedIndicator":"No"},{"value":"Anti-epileptics","valueDescription":"Anticonvulsant Agent","ValueMeaning":{"publicId":"3252866","version":"1","preferredName":"Anticonvulsant Agent","longName":"3252866","preferredDefinition":"(an-tee-kon-VUL-sants) Drugs that prevent, reduce, or stop convulsions or seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticonvulsant Agent","conceptCode":"C264","definition":"Medicine to stop, prevent, or control seizures (convulsions).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7F6FE08-9DA9-3DAF-E040-BB89AD43770F","latestVersionIndicator":"Yes","beginDate":"2011-07-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C3E3C9B-6652-215F-E053-F662850A6F10","beginDate":"2018-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","deletedIndicator":"No"},{"value":"Cellular therapy","valueDescription":"Cellular Therapy","ValueMeaning":{"publicId":"4666954","version":"1","preferredName":"Cellular Therapy","longName":"4666954","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CA258B6-2CAE-90DB-E050-BB89AD4330D1","latestVersionIndicator":"Yes","beginDate":"2015-01-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759AF116-8A56-3969-E053-F662850A3326","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Thalidomide","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"2568117","version":"1","preferredName":"Thalidomide","longName":"2568117","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D722-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-26","modifiedBy":"REEVESD","dateModified":"2016-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D69D-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Pomalidomide","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D6A7-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Carfilzomib","valueDescription":"Carfilzomib","ValueMeaning":{"publicId":"3378843","version":"1","preferredName":"Carfilzomib","longName":"3378843","preferredDefinition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carfilzomib","conceptCode":"C52196","definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17EC-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D6B1-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Sunitinib","valueDescription":"Sunitinib","ValueMeaning":{"publicId":"3107588","version":"1","preferredName":"Sunitinib","longName":"3107588","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-10C5-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D6BB-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Quizartinib","valueDescription":"Quizartinib","ValueMeaning":{"publicId":"6429348","version":"1","preferredName":"Quizartinib","longName":"6429348","preferredDefinition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quizartinib","conceptCode":"C68936","definition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D6C5-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D6DE-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Lestaurtinib","valueDescription":"Lestaurtinib","ValueMeaning":{"publicId":"6429349","version":"1","preferredName":"Lestaurtinib","longName":"6429349","preferredDefinition":"An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lestaurtinib","conceptCode":"C48402","definition":"An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D6E8-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D701-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Gilteritinib","valueDescription":"Gilteritinib","ValueMeaning":{"publicId":"6429350","version":"1","preferredName":"Gilteritinib","longName":"6429350","preferredDefinition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gilteritinib","conceptCode":"C116722","definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D70B-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D724-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Fecal matter transplant","valueDescription":"Fecal Microbiota Transplantation","ValueMeaning":{"publicId":"7154916","version":"1","preferredName":"Fecal Microbiota Transplantation","longName":"7154916","preferredDefinition":"The transplantation of fecal bacteria, via enema, colonoscopy, or other method, from a healthy individual to a recipient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fecal Microbiota Transplantation","conceptCode":"C118643","definition":"The transplantation of fecal bacteria, via enema, colonoscopy, or other method, from a healthy individual to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D39EBCB-58AE-3A21-E053-F662850A95A6","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D39EBCB-58C7-3A21-E053-F662850A95A6","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"IDH2 Inhibitor","valueDescription":"IDH2 inhibitor","ValueMeaning":{"publicId":"7159110","version":"1","preferredName":"IDH2 inhibitor","longName":"7159110","preferredDefinition":"Any agent that inhibits isocitrate dehydrogenase (IDH) type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) found in the mitochondria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IDH2 inhibitor","conceptCode":"C168619","definition":"Any agent that inhibits isocitrate dehydrogenase (IDH) type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) found in the mitochondria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DD547B7-F687-11F3-E053-F662850A90FE","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DD547B7-F6A0-11F3-E053-F662850A90FE","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","deletedIndicator":"No"},{"value":"IDH1 Inhibitor","valueDescription":"IDH1 inhibitor","ValueMeaning":{"publicId":"7159111","version":"1","preferredName":"IDH1 inhibitor","longName":"7159111","preferredDefinition":"Any agent that inhibits isocitrate dehydrogenase (IDH) type 1 (IDH1, IDH1 [NADP+] soluble) found in the cytoplasm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IDH1 inhibitor","conceptCode":"C168618","definition":"Any agent that inhibits isocitrate dehydrogenase (IDH) type 1 (IDH1, IDH1 [NADP+] soluble) found in the cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DD547B7-F6AC-11F3-E053-F662850A90FE","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DD547B7-F6C5-11F3-E053-F662850A90FE","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","deletedIndicator":"No"},{"value":"Bosutinib","valueDescription":"Bosutinib","ValueMeaning":{"publicId":"3379565","version":"1","preferredName":"Bosutinib","longName":"3379565","preferredDefinition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bosutinib","conceptCode":"C60809","definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-371C-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D742-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Imatinib mesylate","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759B430D-D72E-045F-E053-F662850AB8F5","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Panobinostat","valueDescription":"Panobinostat","ValueMeaning":{"publicId":"3379455","version":"1","preferredName":"Panobinostat","longName":"3379455","preferredDefinition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panobinostat","conceptCode":"C66948","definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2334-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8020F6CD-D96F-1E61-E053-F662850A86F8","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Selinexor","valueDescription":"Selinexor","ValueMeaning":{"publicId":"6618084","version":"1","preferredName":"Selinexor","longName":"6618084","preferredDefinition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selinexor","conceptCode":"C102546","definition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801EA03E-93C2-7862-E053-F662850A4F83","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-93DB-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Oprozomib","valueDescription":"Oprozomib","ValueMeaning":{"publicId":"4740632","version":"1","preferredName":"Oprozomib","longName":"4740632","preferredDefinition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oprozomib","conceptCode":"C91388","definition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10D8E2A9-2FD8-D0DE-E050-BB89AD435EC5","latestVersionIndicator":"Yes","beginDate":"2015-03-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-93E5-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Isatuximab","valueDescription":"Isatuximab","ValueMeaning":{"publicId":"6618086","version":"1","preferredName":"Isatuximab","longName":"6618086","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isatuximab","conceptCode":"C90578","definition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801EA03E-93F2-7862-E053-F662850A4F83","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"COOPERM","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-940B-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Interferon-","valueDescription":"Interferon Alpha","ValueMeaning":{"publicId":"3185133","version":"1","preferredName":"Interferon Alpha","longName":"3185133","preferredDefinition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha","conceptCode":"C20494","definition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2CB-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-941F-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Elotuzumab","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-9429-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Daratumumab","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-9433-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Clarithromycin","valueDescription":"Clarithromycin","ValueMeaning":{"publicId":"2577826","version":"1","preferredName":"Clarithromycin","longName":"2577826","preferredDefinition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clarithromycin","conceptCode":"C1054","definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-943D-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Marizomib","valueDescription":"Marizomib","ValueMeaning":{"publicId":"5621726","version":"1","preferredName":"Marizomib","longName":"5621726","preferredDefinition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marizomib","conceptCode":"C64634","definition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC0F-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CC7D8CB-99AB-52B4-E053-F662850A30D6","beginDate":"2019-07-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"Propylene glycol-free melphalan","valueDescription":"Melphalan Hydrochloride","ValueMeaning":{"publicId":"6592216","version":"1","preferredName":"Melphalan Hydrochloride","longName":"6592216","preferredDefinition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan Hydrochloride","conceptCode":"C48002","definition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D384416-6457-1487-E053-F662850AF67B","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90117F29-20B8-0D46-E053-F662850A44A2","beginDate":"2019-08-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-08-14","modifiedBy":"ONEDATA","dateModified":"2019-08-14","deletedIndicator":"No"},{"value":"Other JAK1 or JAK2 inhibitor","valueDescription":"Other JAK1 Inhibitor Or JAK2 Inhibitor Therapeutic Procedure","ValueMeaning":{"publicId":"7134887","version":"1","preferredName":"Other JAK1 Inhibitor Or JAK2 Inhibitor Therapeutic Procedure","longName":"7134887","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"JAK1 Inhibitor","conceptCode":"C129650","definition":"Any substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBAC97C-C917-2F3F-E053-F662850A5306","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBAC97C-C930-2F3F-E053-F662850A5306","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBAC97C-C93A-2F3F-E053-F662850A5306","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBAC97C-C944-2F3F-E053-F662850A5306","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Fedratinib","valueDescription":"Fedratinib","ValueMeaning":{"publicId":"7134889","version":"1","preferredName":"Fedratinib","longName":"7134889","preferredDefinition":"An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fedratinib","conceptCode":"C88293","definition":"An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBAC97C-C951-2F3F-E053-F662850A5306","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBAC97C-C96A-2F3F-E053-F662850A5306","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Androgen","valueDescription":"Androgen","ValueMeaning":{"publicId":"3554908","version":"1","preferredName":"Androgen","longName":"3554908","preferredDefinition":"A type of hormone that promotes the development and maintenance of male sex characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Androgen","conceptCode":"C2298","definition":"A type of hormone that promotes the development and maintenance of male sex characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C740F5C7-7724-BDA9-E040-BB89AD434D2D","latestVersionIndicator":"Yes","beginDate":"2012-08-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BBAC97C-C974-2F3F-E053-F662850A5306","beginDate":"2020-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Liposomal daunorubicin/cytarabine","valueDescription":"Liposome-encapsulated Daunorubicin-Cytarabine","ValueMeaning":{"publicId":"7154914","version":"1","preferredName":"Liposome-encapsulated Daunorubicin-Cytarabine","longName":"7154914","preferredDefinition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposome-encapsulated Daunorubicin-Cytarabine","conceptCode":"C67504","definition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D392C92-8BDA-5364-E053-F662850ABFD8","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-28","modifiedBy":"COLBERTM","dateModified":"2023-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D392C92-8BF3-5364-E053-F662850ABFD8","beginDate":"2020-01-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Checkpoint Inhibitors","valueDescription":"Immune Checkpoint Inhibitor","ValueMeaning":{"publicId":"7150349","version":"1","preferredName":"Immune Checkpoint Inhibitor","longName":"7150349","preferredDefinition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Checkpoint Inhibitor","conceptCode":"C143250","definition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D225969-19FA-5B98-E053-F662850A0BC7","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D225969-1A13-5B98-E053-F662850A0BC7","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Immune therapy","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D225969-1A28-5B98-E053-F662850A0BC7","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Antithymocyte globulin (ATG)","valueDescription":"Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"3253646","version":"1","preferredName":"Anti-Thymocyte Globulin","longName":"3253646","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7AB2-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D211350-AF61-22BC-E053-F662850A18C7","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Luspatercept","valueDescription":"Luspatercept","ValueMeaning":{"publicId":"7150067","version":"1","preferredName":"Luspatercept","longName":"7150067","preferredDefinition":"A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. luspatercept acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luspatercept","conceptCode":"C104012","definition":"A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. luspatercept acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D211350-AF6E-22BC-E053-F662850A18C7","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D211350-AF87-22BC-E053-F662850A18C7","beginDate":"2020-01-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Deferasirox","valueDescription":"Deferasirox","ValueMeaning":{"publicId":"2939024","version":"1","preferredName":"Deferasirox","longName":"2939024","preferredDefinition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferasirox","conceptCode":"C48384","definition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A44-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2EFB733-83F8-37EC-E053-F662850A5281","beginDate":"2020-04-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-04-10","modifiedBy":"ONEDATA","dateModified":"2020-04-10","deletedIndicator":"No"},{"value":"Deferoxamine","valueDescription":"Deferoxamine","ValueMeaning":{"publicId":"7135786","version":"1","preferredName":"Deferoxamine","longName":"7135786","preferredDefinition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferoxamine","conceptCode":"C416","definition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-6178-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2EFB733-83E4-37EC-E053-F662850A5281","beginDate":"2020-04-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-04-10","modifiedBy":"ONEDATA","dateModified":"2020-04-10","deletedIndicator":"No"},{"value":"Deferiprone","valueDescription":"Deferiprone","ValueMeaning":{"publicId":"7135785","version":"1","preferredName":"Deferiprone","longName":"7135785","preferredDefinition":"An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferiprone","conceptCode":"C73030","definition":"An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-614B-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2EFB733-83EE-37EC-E053-F662850A5281","beginDate":"2020-04-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-04-10","modifiedBy":"ONEDATA","dateModified":"2020-04-10","deletedIndicator":"No"},{"value":"Voxelotor","valueDescription":"Voxelotor","ValueMeaning":{"publicId":"7331717","version":"1","preferredName":"Voxelotor","longName":"7331717","preferredDefinition":"An orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD).  Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voxelotor","conceptCode":"C152089","definition":"An orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD).  Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7E9ECE8-41A8-201A-E053-4EBD850AA425","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7E9ECE8-41C1-201A-E053-4EBD850AA425","beginDate":"2020-06-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","deletedIndicator":"No"},{"value":"L-Glutamine","valueDescription":"Glutamine","ValueMeaning":{"publicId":"2577904","version":"1","preferredName":"Glutamine","longName":"2577904","preferredDefinition":"A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamine may become a conditionally essential nutrient during certain catabolic states. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glutamine","conceptCode":"C522","definition":"A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamic acid-to-glutamine conversion, in which an ammonia group is added to glutamic acid (catalyzed by glutamine synthase), is of central importance in the regulation of toxic levels of ammonia in the body. This agent is a substrate for the production of both excitatory and inhibitory neurotransmitters (glutamate and GABA) and is also an important source of energy for the nervous system. Glutamine may become a conditionally essential amino acid during certain catabolic states.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA_WA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7E9ECE8-41D5-201A-E053-4EBD850AA425","beginDate":"2020-06-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","deletedIndicator":"No"},{"value":"Crizanlizumab","valueDescription":"Crizanlizumab","ValueMeaning":{"publicId":"7331719","version":"1","preferredName":"Crizanlizumab","longName":"7331719","preferredDefinition":"A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizanlizumab","conceptCode":"C133543","definition":"A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7E9ECE8-41E2-201A-E053-4EBD850AA425","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7E9ECE8-41FB-201A-E053-4EBD850AA425","beginDate":"2020-06-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","deletedIndicator":"No"},{"value":"Promacta","valueDescription":"Eltrombopag Olamine","ValueMeaning":{"publicId":"7351607","version":"1","preferredName":"Eltrombopag Olamine","longName":"7351607","preferredDefinition":"The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eltrombopag Olamine","conceptCode":"C62501","definition":"The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA5A1944-6CE7-774E-E053-4EBD850A7373","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-13","modifiedBy":"ONEDATA","dateModified":"2020-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA5A1944-6D00-774E-E053-4EBD850A7373","beginDate":"2020-07-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-13","modifiedBy":"ONEDATA","dateModified":"2020-07-13","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA5A1944-6D0A-774E-E053-4EBD850A7373","beginDate":"2020-07-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-13","modifiedBy":"ONEDATA","dateModified":"2020-07-13","deletedIndicator":"No"},{"value":"Nplate","valueDescription":"Romiplostim","ValueMeaning":{"publicId":"3228298","version":"1","preferredName":"Romiplostim","longName":"3228298","preferredDefinition":"A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romiplostim","conceptCode":"C52183","definition":"A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15930B7-34BA-8C0F-E040-BB89AD43469C","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA5A1944-6D1E-774E-E053-4EBD850A7373","beginDate":"2020-07-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-13","modifiedBy":"ONEDATA","dateModified":"2020-07-13","deletedIndicator":"No"},{"value":"Anakinra","valueDescription":"Anakinra","ValueMeaning":{"publicId":"7092700","version":"1","preferredName":"Anakinra","longName":"7092700","preferredDefinition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anakinra","conceptCode":"C38717","definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB90-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2AAA67D-8F8C-2419-E053-4EBD850AA44D","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Enoxaparin","valueDescription":"Enoxaparin","ValueMeaning":{"publicId":"2576814","version":"1","preferredName":"Enoxaparin","longName":"2576814","preferredDefinition":"A drug used to prevent blood clots.  It belongs to the family of drugs called anticoagulants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enoxaparin","conceptCode":"C1452","definition":"A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells.  Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8CCE858-FC47-35AD-E053-4EBD850A5A57","beginDate":"2021-01-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-13","modifiedBy":"ONEDATA","dateModified":"2021-01-13","deletedIndicator":"No"},{"value":"Heparin","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8CCE858-FC51-35AD-E053-4EBD850A5A57","beginDate":"2021-01-13","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-13","modifiedBy":"ONEDATA","dateModified":"2021-01-13","deletedIndicator":"No"},{"value":"Corticosteroids (topical GI)","valueDescription":"Gastrointestinal Topical Corticosteroid","ValueMeaning":{"publicId":"7652524","version":"1","preferredName":"Gastrointestinal Topical Corticosteroid","longName":"7652524","preferredDefinition":"Pertaining to the stomach and intestines.: Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal","conceptCode":"C13359","definition":"Pertaining to the stomach and intestines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Topical Corticosteroid","conceptCode":"C29505","definition":"Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AEF7F6-83C0-7B94-E053-4EBD850A0B48","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AEF7F6-83D9-7B94-E053-4EBD850A0B48","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"},{"value":"Corticosteroids (topical skin)","valueDescription":"Skin Topical Corticosteroid","ValueMeaning":{"publicId":"7652525","version":"1","preferredName":"Skin Topical Corticosteroid","longName":"7652525","preferredDefinition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.: Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin","conceptCode":"C12470","definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Topical Corticosteroid","conceptCode":"C29505","definition":"Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AEF7F6-83E6-7B94-E053-4EBD850A0B48","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AEF7F6-83FF-7B94-E053-4EBD850A0B48","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"},{"value":"Corticosteroids (topical inhaled)","valueDescription":"Inhalation Topical Corticosteroid","ValueMeaning":{"publicId":"7652526","version":"1","preferredName":"Inhalation Topical Corticosteroid","longName":"7652526","preferredDefinition":"To draw in with the breath through the nose or mouth.: Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation","conceptCode":"C95464","definition":"To draw in with the breath through the nose or mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Topical Corticosteroid","conceptCode":"C29505","definition":"Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AEF7F6-840C-7B94-E053-4EBD850A0B48","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AEF7F6-8425-7B94-E053-4EBD850A0B48","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"},{"value":"Plasma exchange / plasmapheresis","valueDescription":"Therapeutic Exchange Plasma Or Plasmapheresis","ValueMeaning":{"publicId":"7617080","version":"1","preferredName":"Therapeutic Exchange Plasma Or Plasmapheresis","longName":"7617080","preferredDefinition":"Plasma obtained from a patient who undergoes plasma exchange (also called therapeutic plasmapheresis).: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Exchange Plasma","conceptCode":"C133348","definition":"Plasma obtained from a patient who undergoes plasma exchange (also called therapeutic plasmapheresis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE72EB22-204E-4A91-E053-4EBD850A4180","latestVersionIndicator":"Yes","beginDate":"2021-03-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-26","modifiedBy":"ONEDATA","dateModified":"2021-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE72EB22-2067-4A91-E053-4EBD850A4180","beginDate":"2021-03-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-26","modifiedBy":"ONEDATA","dateModified":"2021-03-26","deletedIndicator":"No"},{"value":"Eculizumab","valueDescription":"Eculizumab","ValueMeaning":{"publicId":"7092697","version":"1","preferredName":"Eculizumab","longName":"7092697","preferredDefinition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eculizumab","conceptCode":"C48386","definition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB45-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE72EB22-2071-4A91-E053-4EBD850A4180","beginDate":"2021-03-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-26","modifiedBy":"ONEDATA","dateModified":"2021-03-26","deletedIndicator":"No"},{"value":"Corticosteroids (topical)","valueDescription":"Topical Corticosteroids","ValueMeaning":{"publicId":"3253644","version":"1","preferredName":"Topical Corticosteroids","longName":"3253644","preferredDefinition":"Any synthetic steroid derivatives exhibiting the same function as the naturally occurring corticosteroid hormones, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Corticosteroid","conceptCode":"C29505","definition":"Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7A67-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1AF2075-3EB2-7542-E053-4EBD850A6EBF","beginDate":"2021-05-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-05-06","modifiedBy":"ONEDATA","dateModified":"2021-05-06","deletedIndicator":"No"},{"value":"Other TKI","valueDescription":"Other Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"5125101","version":"1","preferredName":"Other Tyrosine Kinase Inhibitor","longName":"5125101","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0CEDE4-6E88-E057-E050-BB89AD437DB7","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A19-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Other JAK 2 inhibitor","valueDescription":"Other JAK2 Inhibitor","ValueMeaning":{"publicId":"5125105","version":"1","preferredName":"Other JAK2 Inhibitor","longName":"5125105","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A85B-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A23-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Other interleukin inhibitor","valueDescription":"Other Interleukin Inhibitor","ValueMeaning":{"publicId":"5125055","version":"1","preferredName":"Other Interleukin Inhibitor","longName":"5125055","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interleukin Inhibitor","conceptCode":"C124064","definition":"Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0C1CBC-A7AD-C8AF-E050-BB89AD43161D","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A2D-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"UVB","valueDescription":"Ultraviolet B Radiation","ValueMeaning":{"publicId":"3380292","version":"1","preferredName":"Ultraviolet B Radiation","longName":"3380292","preferredDefinition":"Ultraviolet B Radiation is the 290 to 320 nanometers portion of the sun's radiant electromagnetic energy spectrum, partially absorbed by the Earth's protective stratospheric ozone layer. Recent ozone depletion has permitted more UVB to reach the Earth's surface with a wide range of potentially damaging health effects related to skin, eyes, and immune system. Evidence shows a dose-response relationship between nonmelanoma skin cancer and cumulative exposure to UVB radiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ultraviolet B Radiation","conceptCode":"C27987","definition":"Ultraviolet B Radiation is the 290 to 320 nanometers portion of the sun's radiant electromagnetic energy spectrum, partially absorbed by the Earth's protective stratospheric ozone layer. Recent ozone depletion has permitted more UVB to reach the Earth's surface with a wide range of potentially damaging health effects related to skin, eyes, and immune system. Evidence shows a dose-response relationship between nonmelanoma skin cancer and cumulative exposure to UVB radiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A501-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A37-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Belumosudil (KD025)","valueDescription":"Belumosudil","ValueMeaning":{"publicId":"7614732","version":"1","preferredName":"Belumosudil","longName":"7614732","preferredDefinition":"An orally administered inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belumosudil","conceptCode":"C128786","definition":"An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A44-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A5D-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin","ValueMeaning":{"publicId":"2575656","version":"1","preferredName":"Azithromycin","longName":"2575656","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F495-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A67-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Anti-IL6","valueDescription":"IL6 Receptor Antibody","ValueMeaning":{"publicId":"7614733","version":"1","preferredName":"IL6 Receptor Antibody","longName":"7614733","preferredDefinition":"Any antibody that recognizes an interleukin 6 receptor protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IL6 Receptor Antibody","conceptCode":"C124046","definition":"Any antibody that recognizes an interleukin 6 receptor protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A71-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9A8A-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Other in vivo monoclonal antibody","valueDescription":"Other in vivo Monoclonal Antibody","ValueMeaning":{"publicId":"7613933","version":"1","preferredName":"Other in vivo Monoclonal Antibody","longName":"7613933","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Located or occurring in the body.: An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE4C0526-E2A8-3F43-E053-4EBD850A7B1B","latestVersionIndicator":"Yes","beginDate":"2021-03-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-24","modifiedBy":"ONEDATA","dateModified":"2021-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE4C0526-E2C1-3F43-E053-4EBD850A7B1B","beginDate":"2021-03-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-24","modifiedBy":"ONEDATA","dateModified":"2021-03-24","deletedIndicator":"No"},{"value":"Anti-IL2","valueDescription":"IL2 Receptor Antibody","ValueMeaning":{"publicId":"7614734","version":"1","preferredName":"IL2 Receptor Antibody","longName":"7614734","preferredDefinition":"Any antibody that recognizes an interleukin 2 receptor protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IL2 Receptor Antibody","conceptCode":"C124045","definition":"Any antibody that recognizes an interleukin 2 receptor protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A94-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F33BC-9AAD-657F-E053-4EBD850AFD37","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Iron chelation","valueDescription":"Iron Chelation","ValueMeaning":{"publicId":"7619730","version":"1","preferredName":"Iron Chelation","longName":"7619730","preferredDefinition":"Iron Chelation involves non-covalent coordination bonding between iron and an organic chemical, often as part of an enzyme or protein complex, as in the iron-binding porphyrin group of hemoglobin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iron Chelation","conceptCode":"C40516","definition":"Iron Chelation involves non-covalent coordination bonding between iron and an organic chemical, often as part of an enzyme or protein complex, as in the iron-binding porphyrin group of hemoglobin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEC47DEA-E63E-2351-E053-4EBD850AC033","latestVersionIndicator":"Yes","beginDate":"2021-03-30","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-30","modifiedBy":"ONEDATA","dateModified":"2021-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEC47DEA-E657-2351-E053-4EBD850AC033","beginDate":"2021-03-30","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-30","modifiedBy":"ONEDATA","dateModified":"2021-03-30","deletedIndicator":"No"},{"value":"Phlebotomy","valueDescription":"Phlebotomy","ValueMeaning":{"publicId":"2582255","version":"1","preferredName":"Phlebotomy","longName":"2582255","preferredDefinition":"The puncture of a vein with a needle for the purpose of drawing blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phlebotomy","conceptCode":"C28221","definition":"The collection of blood from a vein, most commonly via needle venipuncture.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0E5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2006-11-29","modifiedBy":"ONEDATA","dateModified":"2006-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEC47DEA-E661-2351-E053-4EBD850AC033","beginDate":"2021-03-30","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-30","modifiedBy":"ONEDATA","dateModified":"2021-03-30","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":"Abatacept","ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE4C0C71-E143-3E59-E053-4EBD850A5F3D","beginDate":"2021-03-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-24","modifiedBy":"ONEDATA","dateModified":"2021-03-24","deletedIndicator":"No"},{"value":"Alpha-1 antitrypsin","valueDescription":"Alpha-1-Proteinase Inhibitor Human","ValueMeaning":{"publicId":"7631837","version":"1","preferredName":"Alpha-1-Proteinase Inhibitor Human","longName":"7631837","preferredDefinition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1-Proteinase Inhibitor Human","conceptCode":"C82258","definition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC87F2A-1385-74AF-E053-4EBD850AEF21","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFC87F2A-139E-74AF-E053-4EBD850AEF21","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"ONEDATA","dateModified":"2021-04-12","deletedIndicator":"No"},{"value":"Teclistamab","valueDescription":"Teclistamab","ValueMeaning":{"publicId":"7554850","version":"1","preferredName":"Teclistamab","longName":"7554850","preferredDefinition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teclistamab","conceptCode":"C136823","definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFD69E-EEF2-380D-E053-4EBD850ADDF3","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9BFD69E-EF0B-380D-E053-4EBD850ADDF3","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","deletedIndicator":"No"},{"value":"Talquetamab","valueDescription":"Talquetamab","ValueMeaning":{"publicId":"7554852","version":"1","preferredName":"Talquetamab","longName":"7554852","preferredDefinition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talquetamab","conceptCode":"C171840","definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFD69E-EF18-380D-E053-4EBD850ADDF3","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"KUMMEROA","dateModified":"2021-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9BFD69E-EF31-380D-E053-4EBD850ADDF3","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","deletedIndicator":"No"},{"value":"Iberdomide","valueDescription":"Iberdomide","ValueMeaning":{"publicId":"7554854","version":"1","preferredName":"Iberdomide","longName":"7554854","preferredDefinition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iberdomide","conceptCode":"C129048","definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFD69E-EF3E-380D-E053-4EBD850ADDF3","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9BFD69E-EF57-380D-E053-4EBD850ADDF3","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","deletedIndicator":"No"},{"value":"Belantamab mafodotin","valueDescription":"Belantamab Mafodotin","ValueMeaning":{"publicId":"7554856","version":"1","preferredName":"Belantamab Mafodotin","longName":"7554856","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belantamab Mafodotin","conceptCode":"C114299","definition":"An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFD69E-EF64-380D-E053-4EBD850ADDF3","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9BFD69E-EF7D-380D-E053-4EBD850ADDF3","beginDate":"2021-01-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-25","modifiedBy":"ONEDATA","dateModified":"2021-01-25","deletedIndicator":"No"},{"value":"Mesenchymal stem cells (MSCs)","valueDescription":"Mesenchymal Stem Cell","ValueMeaning":{"publicId":"4197222","version":"1","preferredName":"Mesenchymal Stem Cell","longName":"4197222","preferredDefinition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesenchymal Stem Cell","conceptCode":"C43423","definition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F1A516-3B13-2DD9-E040-BB89AD434115","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2014-03-06","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE5F4378-4CCF-44A4-E053-4EBD850A4063","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Corticosteroids - Pulse dose","valueDescription":"Pulse Steroids","ValueMeaning":{"publicId":"7797672","version":"1","preferredName":"Pulse Steroids","longName":"7797672","preferredDefinition":"Intermittent therapeutic administration of high doses of steroids over short periods of time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulse Steroids","conceptCode":"C182447","definition":"Intermittent therapeutic administration of high doses of steroids over short periods of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE15B07E-F6F0-19D0-E053-4EBD850ACFE8","latestVersionIndicator":"Yes","beginDate":"2021-10-11","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-11","modifiedBy":"ONEDATA","dateModified":"2021-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE15B07E-F709-19D0-E053-4EBD850ACFE8","beginDate":"2021-10-11","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-11","modifiedBy":"ONEDATA","dateModified":"2021-10-11","deletedIndicator":"No"},{"value":"GTE:GTO oil (Lorenzo's oil)","valueDescription":"Lorenzo's Oil","ValueMeaning":{"publicId":"7681465","version":"1","preferredName":"Lorenzo's Oil","longName":"7681465","preferredDefinition":"An orally-administered oil composed of the monounsaturated fatty acids glyceryl trioleate (GTO), the triacylglycerol form of oleic acid derived from olive oil, and glyceryl trierucate (GTE), the triacylglycerol form of erucic acid derived from rapeseed oil, in a 4:1 ratio, that can be used in the treatment of adrenoleukodystrophy (ALD). Upon oral administration of Lorenzo's oil, the monounsaturated fatty acids compete with saturated fatty acids as substrates for enzymes in the elongation of very long-chain fatty acids (ELOVL) family. This results in the elongation and production of monounsaturated very long-chain fatty acids (VLCFAs) and reduces the elongation of saturated VLCFAs. This reduces the plasma levels of saturated VLCFAs and prevents their accumulation in the brain, thereby preventing demyelination of cerebral nerves and halting the progression of ALD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorenzo's Oil","conceptCode":"C121561","definition":"An orally-administered oil composed of the monounsaturated fatty acids glyceryl trioleate (GTO), the triacylglycerol form of oleic acid derived from olive oil, and glyceryl trierucate (GTE), the triacylglycerol form of erucic acid derived from rapeseed oil, in a 4:1 ratio, that can be used in the treatment of adrenoleukodystrophy (ALD). Upon oral administration of Lorenzo's oil, the monounsaturated fatty acids compete with saturated fatty acids as substrates for enzymes in the elongation of very long-chain fatty acids (ELOVL) family. This results in the elongation and production of monounsaturated very long-chain fatty acids (VLCFAs) and reduces the elongation of saturated VLCFAs. This reduces the plasma levels of saturated VLCFAs and prevents their accumulation in the brain, thereby preventing demyelination of cerebral nerves and halting the progression of ALD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C447B176-C3F4-0D57-E053-4EBD850A4D4B","latestVersionIndicator":"Yes","beginDate":"2021-06-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-08","modifiedBy":"ONEDATA","dateModified":"2021-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C447B176-C40D-0D57-E053-4EBD850A4D4B","beginDate":"2021-06-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-08","modifiedBy":"ONEDATA","dateModified":"2021-06-08","deletedIndicator":"No"},{"value":"Itacitinib","valueDescription":"Itacitinib","ValueMeaning":{"publicId":"8123275","version":"1","preferredName":"Itacitinib","longName":"8123275","preferredDefinition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itacitinib","conceptCode":"C116855","definition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB5C2A32-9890-2B68-E053-4EBD850AE122","latestVersionIndicator":"Yes","beginDate":"2022-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-03-29","modifiedBy":"ONEDATA","dateModified":"2022-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB5C2A32-98A9-2B68-E053-4EBD850AE122","beginDate":"2022-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-03-29","modifiedBy":"ONEDATA","dateModified":"2022-03-29","deletedIndicator":"No"},{"value":"KGF","valueDescription":"Fibroblast Growth Factor 7","ValueMeaning":{"publicId":"2644088","version":"1","preferredName":"Fibroblast Growth Factor 7","longName":"2644088","preferredDefinition":"Fibroblast Growth Factor 7 (Keratinocyte Growth Factor) is a member of the fibroblast growth factor family that stimulates the growth of epithelial cells, but lacks mitogenic activity on fibroblasts or endothelial cells.  FGF7 is a single polypeptide chain of about 28 kD that has predominant activity in keratinocytes.  (from OMIM 148180 and NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibroblast Growth Factor 7","conceptCode":"C20436","definition":"Fibroblast growth factor 7 (194 aa, ~23 kDa) is encoded by the human FGF7 gene. This protein is involved in embryonic development, cell proliferation, cell differentiation, branch formation and keratinocyte growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31378E67-E710-69CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-24","endDate":null,"createdBy":"GUEST","dateCreated":"2007-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAF7EEFE-FF83-466B-E053-4EBD850A774E","beginDate":"2022-03-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-03-24","modifiedBy":"ONEDATA","dateModified":"2022-03-24","deletedIndicator":"No"},{"value":"Evusheld","valueDescription":null,"ValueMeaning":{"publicId":"12112943","version":"1","preferredName":"Cilgavimab/Tixagevimab","longName":"12112943v1.00","preferredDefinition":"A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cilgavimab/Tixagevimab","conceptCode":"C175229","definition":"A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE15CE49-D4D9-2E3B-E053-731AD00A28FE","latestVersionIndicator":"Yes","beginDate":"2022-11-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-22","modifiedBy":"KUMMEROA","dateModified":"2022-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EE15CE49-D4DA-2E3B-E053-731AD00A28FE","beginDate":"2022-11-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-22","modifiedBy":"KUMMEROA","dateModified":"2022-11-22","deletedIndicator":"No"},{"value":"Emapalumab","valueDescription":null,"ValueMeaning":{"publicId":"12151552","version":"1","preferredName":"Emapalumab","longName":"12151552v1.00","preferredDefinition":"A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emapalumab","conceptCode":"C127123","definition":"A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EFE1FC5B-AD6E-54B8-E053-731AD00AC83E","latestVersionIndicator":"Yes","beginDate":"2022-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-15","modifiedBy":"KUMMEROA","dateModified":"2022-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EFE1FC5B-AD6F-54B8-E053-731AD00AC83E","beginDate":"2022-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-15","modifiedBy":"KUMMEROA","dateModified":"2022-12-15","deletedIndicator":"No"},{"value":"Antiviral drugs","valueDescription":null,"ValueMeaning":{"publicId":"3235629","version":"1","preferredName":"Antiviral Agent","longName":"3235629","preferredDefinition":"Drugs used to treat infections caused by viruses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A369A0EE-1117-2F9A-E040-BB89AD430C53","latestVersionIndicator":"Yes","beginDate":"2011-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83A-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Decorporation drugs","valueDescription":null,"ValueMeaning":{"publicId":"14718278","version":"1","preferredName":"Radionuclide Decorporation Agent","longName":"14718278v1.00","preferredDefinition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radionuclide Decorporation Agent","conceptCode":"C120558","definition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA00F0C-B836-6917-E063-731AD00A9504","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83B-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Growth factors","valueDescription":null,"ValueMeaning":{"publicId":"2918795","version":"1","preferredName":"Growth Factor","longName":"2918795","preferredDefinition":"Substances made by the body that function to regulate cell division and cell survival. Some growth factors are also produced in the laboratory and used in biological therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Growth Factor","conceptCode":"C20424","definition":"Growth Factors are extracellular signaling molecules (ligands) involved in control of target cell proliferation, cell survival, and cell differentiation. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6EA59D2C-DD3F-E897-E040-BB89AD430AFD","latestVersionIndicator":"Yes","beginDate":"2009-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83C-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Non-absorbable oral antibiotics","valueDescription":null,"ValueMeaning":{"publicId":"2799757","version":"1","preferredName":"Negation Absorbable Oral Route of Administration Antibiotic","longName":"2799757v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Capable of being taken up or taken in._The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins._Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Absorbable","conceptCode":"C75520","definition":"Capable of being taken up or taken in.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B94640F-EE11-66D8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-13","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83D-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Platelet transfusion","valueDescription":null,"ValueMeaning":{"publicId":"2562784","version":"1","preferredName":"Platelet transfusion","longName":"2562784v1.00","preferredDefinition":"The infusion of platelets into the bloodstream.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platelet Transfusion","conceptCode":"C15366","definition":"The infusion of platelets into the bloodstream.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C24D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83E-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-25","deletedIndicator":"No"},{"value":"RBC transfusion","valueDescription":null,"ValueMeaning":{"publicId":"14718279","version":"1","preferredName":"Erythrocyte Blood Transfusion","longName":"14718279v1.00","preferredDefinition":"A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans._The injection of whole blood or a blood component directly into the bloodstream.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythrocyte","conceptCode":"C12521","definition":"A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Blood Transfusion","conceptCode":"C15192","definition":"The injection of whole blood or a blood component directly into the bloodstream.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA00F0C-B837-6917-E063-731AD00A9504","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B83F-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-25","deletedIndicator":"No"},{"value":"Systemic antibacterial antibiotics","valueDescription":null,"ValueMeaning":{"publicId":"14718280","version":"1","preferredName":"Systemic Therapy Antibacterial Agent","longName":"14718280v1.00","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._A family of substances capable of destroying or inhibiting the growth of bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibacterial Agent","conceptCode":"C52588","definition":"A family of substances capable of destroying or inhibiting the growth of bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA00F0C-B838-6917-E063-731AD00A9504","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B840-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Systemic antifungal drugs","valueDescription":null,"ValueMeaning":{"publicId":"14718281","version":"1","preferredName":"Systemic Therapy Antifungal Agent","longName":"14718281v1.00","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA00F0C-B839-6917-E063-731AD00A9504","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA00F0C-B841-6917-E063-731AD00A9504","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":null,"ValueMeaning":{"publicId":"3951357","version":"1","preferredName":"Corticosteroid","longName":"3951357","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BCFE-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10415D4A-05D9-272B-E063-731AD00AC57F","beginDate":"2024-01-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-31","modifiedBy":"KUMMEROA","dateModified":"2024-01-31","deletedIndicator":"No"},{"value":"Erythropoietin","valueDescription":null,"ValueMeaning":{"publicId":"2644085","version":"1","preferredName":"Erythropoietin","longName":"2644085","preferredDefinition":"Glycoprotein hormone, secreted chiefly by the kidney in the adult and the liver in the fetus, that acts on erythroid stem cells of the bone marrow to stimulate proliferation and differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythropoietin","conceptCode":"C20429","definition":"Erythropoietin (193 aa, ~21 kDa) is encoded by the human EPO gene. This protein plays a role in both erythropoiesis and the maintenance of red blood cell volume.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31378E67-E6E9-69CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-24","endDate":null,"createdBy":"GUEST","dateCreated":"2007-05-24","modifiedBy":"COLBERTM","dateModified":"2023-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106C1563-F5BE-74F0-E063-731AD00A9A23","beginDate":"2024-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-02-02","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","deletedIndicator":"No"},{"value":"HCT","valueDescription":null,"ValueMeaning":{"publicId":"4395931","version":"1","preferredName":"Hematopoietic Cell Transplantation","longName":"4395931","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBB1E93-3F07-E882-E040-BB89AD431336","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-07-21","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106C1563-F5BF-74F0-E063-731AD00A9A23","beginDate":"2024-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-02-02","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2749690","version":"1","preferredName":"Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D35F706-1F30-4E8C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-14","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-05-14","modifiedBy":"ONEDATA","dateModified":"2008-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F872-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","changeDescription":".Added PVs for 4000. AK 5/16/17 Added PVs for 4100r5. AK 9/11/18 Added PVs for 2016r4. AK 1/23/19 Added PV for 2016. AK 7/3/19 PVs added. AK 2020-1-9. Added PVs for F2014r4 and F2114r4. 01/27/2020 KMM. Added PVs for F2014r4 and F2114r4. 01/28/2020 KMM Added 3 PVs for 2030. AK 2020-4-10. Added PVs for 2030r3. 06/12/2020 KMM. PVs added. 07/13/2020 KMM. PVs added for 2450r6. 01/13/2021 KMM. Added PVs for 2016r5. 01/25/2021 KMM 2021-1-26 ak Added PV def for existing PV for KM. PVs added for 2100r7. 03/23/2021 KMM. PVs added for 2100r7. 03/25/2021 KMM. PVs added for 2100r7. 03/26/2021 KMM. PVs added for 2100r7. 03/30/2021 KMM. PVs added for 2100r7. 04/05/2021 KMM Removed dupe PV for KM. 2021-4-8 ak. PVs added for 2100r7. 04/12/2021 KMM. PVs added for 2100r7. 04/13/2021 KMM. Added PV for Epic. 05/06/2021 KMM. PV added for 2037r3. 06/08/2021 KMM. PV added for 2400r10. 03/24/2022 KMM. PV added for 4000r9. 03/29/2022 KMM","administrativeNotes":"2024.2.2 PVs added per ticket request CADSR0003360. ak 2024.1.31 PV added per ticket request CADSR0003349. ak 2024.1.23 PVs added per ticket request CADSR0003319. ak 2022.12.15 PV added for ticket request CADSR0001804. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_OF_liv_tox_prev_th_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the liver toxicity p","type":"Preferred Question Text","description":"What was the liver toxicity preventive intervention administered?","url":null,"context":"NHLBI"},{"name":"Specify therapy used to prevent liver toxicity","type":"Application Standard Question Text","description":"Specify therapy used to prevent liver toxicity","url":null,"context":"NHLBI"},{"name":"Specify therapy used to prevent liver toxicity","type":"Alternate Question Text","description":"Specify therapy used to prevent liver toxicity","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE738A6C-6B79-424B-E053-4EBD850AC102","latestVersionIndicator":"Yes","beginDate":"2021-03-26","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-26","modifiedBy":"MALUMK","dateModified":"2021-10-04","changeDescription":"Released. 07/27/2021 KMM; System generated def displayed as alt def. ALT name added for 2100r7. 10/04/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}